Evidence for tissue factor phosphorylation and its correlation with protease‐activated receptor expression and the prognosis of primary breast cancer
Open Access
- 30 September 2009
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 126 (10), 2330-2340
- https://doi.org/10.1002/ijc.24921
Abstract
Tissue factor (TF)‐mediated protease‐activated receptor (PAR)‐2 signaling is associated with a promigratory, invasive and proangiogenic phenotype in experimental models of breast cancer and has been mechanistically coupled to phosphorylation of the TF cytoplasmic domain (pTF). However, the clinical relevance of these findings is unknown. Here, we provide the first in vivo evidence of TF phosphorylation in experimental as well as clinical breast cancer tumors. pTF was demonstrated in MDA‐MB‐231 xenografts and in tumors from the MMTV‐PyMT transgene model of spontaneous murine breast adenocarcinoma. Tumors from PAR‐2–deficient transgenic mice were negative for pTF, thus linking pTF to PAR‐2 signaling. The clinical correlation between TF, pTF, PAR‐1, PAR‐2 and vascular endothelial growth factor (VEGF)‐A was determined by immunohistochemistry on tumors from a cohort of 172 consecutive primary breast cancer patients, with a median follow‐up time of 50 months. In 160 evaluable patient tumors, pTF was associated with TF (p = 0.01) and cancer cell expression of PAR‐1 (p = 0.001), PAR‐2 (p = 0.014) and VEGF‐A (p = 0.003) using χ2 test. PAR‐2 and VEGF‐A were coexpressed (p = 0.013) and associated with a more aggressive phenotype. Interestingly, all patients experiencing recurrences had tumors expressing pTF and PAR‐2, and pTF alone as well as coexpression of pTF and PAR‐2 were significantly correlated with shorter recurrence‐free survival (log rank test, p = 0.04 and p = 0.02, respectively). This study provides the first evidence to link PAR‐2 expression and TF phosphorylation to clinical data in human breast cancer. In conjunction with experimental tumor models, these data support an important role of TF‐PAR‐2 signaling in breast cancer recurrence.Keywords
This publication has 38 references indexed in Scilit:
- Tissue Factor and PAR2 Signaling in the Tumor MicroenvironmentArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Protease-Activated Receptor (PAR) 2, but not PAR1, Signaling Promotes the Development of Mammary Adenocarcinoma in Polyoma Middle T MiceCancer Research, 2008
- Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasionOncogene, 2008
- Inhibition of tissue factor signaling suppresses tumor growthBlood, 2008
- Transcriptional program induced by factor VIIa‐tissue factor, PAR1 and PAR2 in MDA‐MB‐231 cellsJournal of Thrombosis and Haemostasis, 2007
- Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: Analysis of 174 patients after SLN biopsyEuropean Journal of Surgical Oncology, 2007
- Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathwaysBiochemical and Biophysical Research Communications, 2006
- Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and CancerArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Persistent Signaling by Dysregulated Thrombin Receptor Trafficking Promotes Breast Carcinoma Cell InvasionMolecular and Cellular Biology, 2004
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991